SpectraScience, Inc.

SpectraScience, Inc. develops and markets a technology platform to instantly determine whether a tissue is normal, pre-cancerous, or cancerous without the need for a physical biopsy in the United States, Europe, and internationally. It offers WavSTAT3 optical biopsy system to determine whether a colon tissue is normal, pre-cancerous, or cancerous without physically removing tissue from the body; and WavSTAT4 optical biopsy system, a colon diagnostic product that operates by using UV laser light to optically illuminate and analyze tissue, enabling the physician to make an instant diagnosis during endoscopy when screening for cancer. The company also sells mobile consoles and disposable forceps. In addition, it engages in developing an esophageal diagnosis application for the detection of pre-cancerous and cancerous tissues in various tissues of the body. The company was formerly known as GV Medical, Inc. and changed its name to SpectraScience, Inc. in October 1992. SpectraScience, Inc. was founded in 1983 and is based in San Diego, California.

SpectraScience, Inc. trades as SCIE on OTC. The company is classified in Healthcare / Medical - Specialties and reports in USD.

The current profile places the business in Medical - Specialties. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

SpectraScience, Inc. can be compared against peers such as Arno Therapeutics, Inc., Better Therapeutics, Inc., Calithera Biosciences, Inc., Dermisonics, Inc., IMRIS Inc., Inyx, Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $4,924, beta of -30.43, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

SCIE currently shows total debt of N/A and beta of -30.43. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.spectrascience.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.